Jan Gray Joins Resverlogix Board of Directors

    TSX Exchange Symbol: RVX

    CALGARY, July 25 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) is pleased to announce effective immediately Jan Gray, CA
has joined the Company's Board of Directors. On the subject of her appointment
Jan Gray said, "Working with Resverlogix represents an exciting opportunity
for me. The Company has done a wonderful job moving forward its lead drug into
clinical trials. I expect the next foreseeable future to be both busy and very
exciting. I am delighted to be joining the Board of Resverlogix."
    "Jan's background as a chartered accountant adds a new skill set to the
current Board of Directors, which is fundamental to the operation of the group
in today's complex financial reporting environment. We are very pleased that
she has agreed to join Resverlogix's Board," stated Donald McCaffrey,
President and CEO of Resverlogix. "Jan brings to us a wealth of strategic and
organizational excellence. In addition to her duties as a Board member Jan
will provide sound counsel to our audit committee."
    Jan Gray, CA is a practicing chartered accountant who specializes in
advising high net worth individuals with complex financial, investment and
taxation issues. She is also Executive Vice-President and Treasurer of
Cartwright Canada Inc., a legal publishing company and Controller of Felesky
Flynn LLP, a regional Alberta law firm. Ms. Gray's prior experience includes
being a former Vice President and Controller of GE Capital Canada and previous
to this she worked for Ernst & Young where she was a Manager in the National
Accounting Group providing quality assurance on large public practice
    Ms. Gray currently serves on the board of directors of GE Money Trust
Company, a unit of General Electric Company and the Auxilium Foundation where
she administers the multi-million dollar charitable fund. In addition Jan is a
regular volunteer with Inn From the Cold, Calgary's only shelter for homeless
families which allows the family to remain together.

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.

    This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.

    %SEDAR: 00019253E E

For further information:

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com; Don
McCaffrey, President & CEO, Resverlogix Corp., Phone: (403) 254-9252, Email:
Don@resverlogix.com; Website: www.resverlogix.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890